Biotechnology - Omigard(TM) Phase III Pivotal Registration Study Enrollment Completed
5/6/2008 12:00:00 PM
[NEWS]MIGENIX to Present at BioFinance and Rodman & Renshaw Conferences in May VANCOUVER and SAN DIEGO, May 6 /PRNewswire-FirstCall/ - MIGENIX Inc.(TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectiousdiseases, has been notified by their partner for Omigard™ in NorthAmerica and Europe; Cadence Pharmaceuticals, Inc. (“Cadence”), that fullenrollment of the pivotal Phase III confirmatory study for preventingcatheter-related infections has been reached (see “Cadence’s Press Rel…
...
full article